Shield Therapeutics Statistics
Want to see GB:STX full AI Analyst Report?
Shield Therapeutics (STX) Stock Statistics & Valuation Metrics
Total Valuation
Shield Therapeutics has a market cap or net worth of GBX 35.45M. The enterprise value is GBX 78.73M.
- Market Cap
- GBX 35.45M
- Enterprise Value
- GBX 78.73M
Share Statistics
Shield Therapeutics has 1,074,193,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,074,193,700
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Shield Therapeutics’s return on equity (ROE) is 1.20 and return on invested capital (ROIC) is -68.36%.
- Return on Equity (ROE)
- 1.20
- Return on Assets (ROA)
- -0.28
- Return on Invested Capital (ROIC)
- -68.36%
- Return on Capital Employed (ROCE)
- -0.68
- Revenue Per Employee
- 831.86K
- Profits Per Employee
- -295.50K
- Employee Count
- 61
- Asset Turnover
- 0.78
- Inventory Turnover
- 3.08
Valuation Ratios
The current PE Ratio of Shield Therapeutics is -4.49. Shield Therapeutics’s PEG ratio is -0.04.
- PE Ratio
- -4.49
- PS Ratio
- 0.81
- PB Ratio
- -2.75
- Price to FCF
- -3.84
- Price to Operating Cash Flow
- -3.84
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Shield Therapeutics had revenue of 50.74M and earned -18.03M in profits. Earnings per share was -0.02.
- Revenue
- 50.74M
- Gross Profit
- 22.38M
- Operating Income
- -10.30M
- Pretax Income
- -17.50M
- Net Income
- -18.03M
- EBITDA
- -9.16M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -12.26M and capital expenditures -51,895, giving a free cash flow of -12.31M billion.
- Operating Cash Flow
- -12.26M
- Free Cash Flow
- -12.31M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Shield Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.90%
- Earnings Yield
- -21.99%
Stock Price Statistics
- Beta
- 1.54
- 52-Week Price Change
- -50.38%
- 50-Day Moving Average
- 5.16
- 200-Day Moving Average
- 6.74
- Relative Strength Index (RSI)
- 28.70
- Average Volume (3m)
- 3.11M
Important Dates
Shield Therapeutics upcoming earnings date is Apr 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Apr 29, 2027
- Ex-Dividend Date
- ―
Financial Position
Shield Therapeutics as a current ratio of 0.90, with Debt / Equity ratio of -199.87%
- Current Ratio
- 0.90
- Quick Ratio
- 0.72
- Debt to Market Cap
- 0.35
- Net Debt to EBITDA
- -2.02
- Interest Coverage Ratio
- -1.36
Taxes
In the past 12 months, Shield Therapeutics has paid 524.78K in taxes.
- Income Tax
- 524.78K
- Effective Tax Rate
- -0.03
Enterprise Valuation
Shield Therapeutics EV to EBITDA ratio is -19.91, with an EV/FCF ratio of -5.21.
- EV to Sales
- 1.10
- EV to EBITDA
- -19.91
- EV to Free Cash Flow
- -5.21
- EV to Operating Cash Flow
- -5.23
Balance Sheet
Shield Therapeutics has GBX 8.39M in cash and marketable securities with GBX 25.03M in debt, giving a net cash position of -GBX 16.64M billion.
- Cash & Marketable Securities
- GBX 8.39M
- Total Debt
- GBX 25.03M
- Net Cash
- -GBX 16.64M
- Net Cash Per Share
- -GBX 0.02
- Tangible Book Value Per Share
- -GBX 0.03
Margins
Gross margin is 50.58%, with operating margin of -7.02%, and net profit margin of -17.76%.
- Gross Margin
- 50.58%
- Operating Margin
- -7.02%
- Pretax Margin
- -16.81%
- Net Profit Margin
- -17.76%
- EBITDA Margin
- -5.51%
- EBIT Margin
- -7.02%
Analyst Forecast
The average price target for Shield Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 36.19%
- EPS Growth Forecast
- 60.75%
Scores
- Smart Score
- 4
- AI Score
- 40
